Author

Sayed Matar

Brigham and Women's HospitalORCID 0000-0002-9687-2318Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 3 Organism:human· 3 Approach:statistical model· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Assay:DNA methylation· 1

Frequent Co-Authors

Sabina SignorettiiD· 3 shared Srinivas Raghavan ViswanathaniD· 3 shared Toni K. ChoueiriiD· 3 shared Yasmin Nabil LaimoniD· 3 shared Cary N. WeissiD· 2 shared Eliezer M. Van AlleniD· 2 shared Gwo‐Shu Mary LeeiD· 2 shared Jiao LiiD· 2 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersGenomics

Sabina SignorettiORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma

Prathyusha Konda, Alexandra J. Wakolbinger, Yantong Cui, Gabriel Roberti De Oliveira, Yasmin Nabil Laimon, Cary N. Weiss, Maxwell D. Seager, Riva Deodhar, Jiao Li, Sayed Matar, Jinyu Wang, Jack T. Horst, Sabrina Yvonne Camp, Aseman Bagheri Sheshdeh, Jonathan L. Hecht, , Srinivas Raghavan Viswanathan

This study identifies fusion-driven oncogenic programs in translocation renal cell carcinoma (tRCC) that shape an immunosuppressive tumor microenvironment, explaining its reduced immunotherapy response.

Nature Communications · Aug 26, 2026Peer-reviewedGenomics

TFE3 fusions direct an oncogenic transcriptional program that drives OXPHOS and unveils vulnerabilities in translocation renal cell carcinoma

Jiao Li, Kaimeng Huang, Meha Thakur, Fiona McBride, Ananthan Sadagopan, Daniel S Gallant, Prateek Khanna, Yasmin Nabil Laimon, Bingchen Li, Razan Assaad Mohanna, Maolin Ge, Cary N. Weiss, Mingkee Achom, Qingru Xu, Sayed Matar, , Srinivas Raghavan Viswanathan

This study identifies TFE3 fusions driving OXPHOS in tRCC and reveals EGLN1 inhibition as a therapeutic target.

Nature Metabolism · Feb 6, 2025Peer-reviewedCancer Biology

Epigenomic signatures as circulating and predictive biomarkers in sarcomatoid renal cell carcinoma

Talal El Zarif, Karl Semaan, Marc Eid, Ji-Heui Seo, Simon Garinet, Matthew P. Davidsohn, Pranshu Sahgal, Brad J. Fortunato, John Canniff, Amin H. Nassar, Sarah Abou Alaiwi, Ziad Bakouny, Gitanjali Lakshminarayanan, Hunter Savignano, Kevin Lyons, , Sylvan C. Baca

The paper identifies epigenomic signatures in sarcomatoid renal cell carcinoma (sRCC) that predict response to immune checkpoint inhibitors and are detectable in plasma, enabling non-invasive diagnosis.

Cell Reports · Jun 1, 2024Peer-reviewedGenomics